Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.
Approval Alert | Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
4
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
5
